Aerpio Pharmaceuticals Inc (NASDAQ:ARPO) registered an increase of 61.2% in shorted shares. In March was published ARPO’s total 223,900 shorted shares by FINRA. The 138,900 previous shares are up with 61.2%. Aerpio Pharmaceuticals Inc (NASDAQ:ARPO) has 110,400 shares average volume. It’ll cost 2 days for ARPO to restore its previous position. Aerpio Pharmaceuticals Inc’s shorted shares float is 0.99%.
The stock increased 10.90% or $0.4 during the last trading session, touching $4.07.Currently Aerpio Pharmaceuticals, Inc. is downtrending after 41.63% change in last March 13, 2018. ARPO has 174,224 shares volume. ARPO underperformed by 46.00% the S&P 500.
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases.The firm is valued at $165.17 million. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy.Last it reported negative earnings. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease.
For more Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) news brought out briefly go to: Benzinga.com, Businesswire.com, , Nasdaq.com or Seekingalpha.com. The titles are as follows: “71 Biggest Movers From Yesterday – Benzinga” brought out on February 20, 2019, “Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy – Business Wire” on January 17, 2019, “The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings – Yahoo Finance” with a publish date: March 05, 2019, “Orange : Financial results at 31 December 2018 (corrected version) – Nasdaq” and the last “Aerpio Pharmaceuticals’ (ARPO) CEO Steve Hoffman on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: November 10, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.